Matt Hancock and Lord Bethell support Randox in call for future focus on diagnostics

Home - Business News

Matt Hancock and Lord Bethell support Randox in call for future focus on diagnostics

News       About Us       COVID-19

 

29 June 2020

Matt Hancock and Lord Bethell support Randox in call for future focus on diagnostics

Matt Hancock and Lord Bethell support Randox in call for future focus on diagnostics

In a recent Opinion Piece in The Daily Telegraph, our Managing Director Dr Peter FitzGerald stressed the value of diagnostics, the important role it plays in public health, and the contribution it has made specifically during the COVID-19 pandemic.

Whilst regrettable that it has taken a pandemic to bring the health diagnostics sector into focus, it is a positive step forward for healthcare that the huge national and international scope of our sector is now rightly acknowledged.

Indeed, Dr FitzGerald’s commentary was acknowledged by both the Secretary of State for Health, Matt Hancock, and the Minister for Innovation, Jim Bethell.

The Secretary of State noted that “Randox have played a vital role in building our global-scale diagnostics capacity.”

    It is clear that the diagnostics industry, inclusive of the work Randox has done in the field, has had a positive impact in the fight against COVID-19. We know that testing at scale is the most effective way to both save lives, and ensure a timely return to a more normal society.

    We are very proud of our staff, for their ongoing support, and for their commitment to the work that we do, which is making a real and positive difference.

    You can read Dr FitzGerald’s full Opinion Piece for The Daily Telegraph, on our own website, by clicking here.

    For further information please contact randoxpr@randox.com or phone 028 9442 2413

    Want to know more about Randox?

    Contact us or visit our homepage to view more.

    Our Randox Products and Services

    REAGENTS

    RX SERIES

    ACUSERA

    BIOCHIP


    COVID-19 has shown UK leadership on diagnostics; we can now become a world leader

    News       About Us       COVID-19

     

    25 June 2020

    COVID-19 has shown UK leadership on diagnostics

    COVID-19 has shown UK leadership on diagnostics; we can now become a world leader

    An Opinion Piece by Dr Peter FitzGerald, Managing Director of Randox Laboratories, in The Daily Telegraph

    When I founded Randox Laboratories in 1982 in Antrim, Northern Ireland, I could not have envisaged that today we would be manufacturing more clinical diagnostic products than any other company in the UK. Whilst I am incredibly proud that Randox is taking a leading role in the national Covid-19 testing effort, it is deeply regrettable that it has taken this pandemic to bring the UK’s health diagnostics sector into focus.

    The pandemic represents the biggest diagnostics and health infrastructure challenge of modern times.  It has forced and necessitated a herculean collaborative effort from Government, the NHS and the private sector. This partnership has delivered a new trust and information sharing network which bodes well for the future.

    Ministers now know what we can do and rightly acknowledge the huge national and international scope of our sector and for global UK leadership and new skilled jobs.  The Government is right to highlight and reflect that too many of these critical sectors and supplies have been allowed to be offshored in recent years. This has consequently had implications for patient care and the support available for health workers.

    In March, the World Health Organisation’s Director General, Tedros Adhanom Ghebreyesus, said that he had a simple message to countries on how to deal with the COVID-19 outbreak that was sweeping the globe, this message was ‘Test, test, test.’ In the UK, mass testing was, at that time, simply not possible. Indeed, the Health Secretary, Matthew Hancock, acknowledged  that it was the lack of a significant domestic diagnostic industry that had impeded the Government’s initial efforts on testing, which is why we were behind Germany and other states.  He was right and much has already been done to re-shore capacity and re-set this policy alongside understanding the importance for future British sector leadership.

    Going forward, we can and must deliver a new and much tighter partnership between the NHS and private sector across diagnostics and preventative healthcare. Improved communication, co-operation and partnerships will grow British sector expertise, jobs and skills.  The potential for British leadership and success here is huge.

    Earlier this month, I had the pleasure of welcoming Northern Ireland Secretary, Brandon Lewis MP to see our new £30m specialist Covid-19 testing hub at the Randox Science Park in Northern Ireland.  This investment will create 200 new science, engineering and manufacturing jobs at the facility on top of our existing workforce. It was fast-tracked over the space of four weeks and is the first step in a wider diagnostics investment programme as part of Randox’s efforts to enhance our national Covid testing capacity.

    A wider appreciation of the value and resource support for diagnostics testing and preventative health policy is now overdue and timely especially when you consider that seventy per cent of all medical decisions are based on the results of lab tests.  This testing must now account for more than the two per cent of the national healthcare budget.   Alongside our major focus on R&D, our scientists work on pioneering research into a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease. With around twenty five percent of turnover reinvested in R&D, Randox has more new tests in development than any other diagnostic company.  Our products are used across hospitals and veterinary laboratories, food testing, forensic toxicology and life sciences.

    Randox labs have spent over £305 million researching the thousands of biomarkers present in our bodies and have identified the gold standard in testing. Our patented Biochip Array Technology has revolutionized the diagnostics industry by offering a unique testing platform which allows multiple tests to be carried out from a single patient sample. On Covid, we have been able to include two tests on the same biochip; one specific and one confirmatory as recommended by the World Health Organisation.

    The ambition and determination to build a world-beating British diagnostics sector is overdue and right.  It offers so many advantages ranging from a healthier and happier population which lives longer to more skilled jobs in a sector which works hand in glove with our world beating academia and NHS.  The pandemic has rightly brought the UK’s diagnostics capability into sharp focus, and it is paramount that when we move to a post-Covid world, we take what we have learned from this crisis and build a self-reliant sector fit for the future.

      For further information please email randoxpr@randox.com

       

      Want to know more about Randox?

      Contact us or visit our homepage to view more.

      Our Randox Products and Services

      REAGENTS

      RX SERIES

      ACUSERA

      BIOCHIP


      Randox announces its £30m investment in specialised COVID-19 testing lab

      News       About Us       COVID-19

       

      03 June 2020

      Randox invests £30m and 200 new jobs in specialised COVID-19 testing lab

      Randox invests £30m and 200 new jobs in specialised COVID-19 testing lab

      As part of efforts to enhance its national testing capacity, global diagnostics company Randox has announced an investment of £30m in a new specialised COVID-19 testing hub.

      The healthcare firm, which is currently conducting COVID-19 tests as part of the national testing programme, announced its investment in the new facilities based at the Randox Science Park in Antrim, Northern Ireland, during a visit yesterday by the Secretary of State for Northern Ireland, The Rt Hon Brandon Lewis CBE.

      The specialised laboratory, the development of which was fast-tracked over the space of four weeks, is the first step in a wider diagnostics investment programme from Randox.

      Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;

      “The national testing programme, as a collaborative effort by government and various partners within industry, has increased testing capacity at an unparalleled speed – by installing a network of drive-through testing centres, introducing home testing kits, and now, opening this specialised lab at the Randox Science Park in Northern Ireland.

      “An incredible amount of work has gone into making this cutting-edge testing facility a reality in a relatively short space of time, as we know that effective testing is the most effective way to both save lives and promote a timely return to a more normal society.”

      The opening of the new laboratory at the Randox Science Park follows the company’s announcement that it is recruiting new staff across Science, Engineering and Manufacturing in support of its role within the national testing programme.

      The 200 new positions will be involved in the testing of potential COVID-19 samples, as well as the construction of 200 new state-of-the-art diagnostic analysers which will significantly increase Randox’s capacity for COVID-19 testing.

      Dr FitzGerald continued;

      “Now that we have in place the infrastructure and laboratory space required to enhance our testing capacity, we look forward to implementing the next step in our COVID-19 investment programme.

      “By accelerating the build schedule for new specialised equipment, and hiring 200 associated workers across Science, Engineering and Manufacturing we will further enhance the government’s national testing scheme, as well as facilitate testing more broadly across the general populace.”

      Secretary of State Brandon Lewis MP welcomed the new investment saying:

      “I was impressed during my visit with the dedication of staff and the top-class facilities at Randox. This investment will help support the UK’s nationwide effort to fight the coronavirus and ultimately save lives.”  

      Dr FitzGerald concluded;

      “I would also like to take this opportunity to pay tribute to all my colleagues at Randox who continue to work assiduously to process such a high volume of tests in a timely manner.

      “I know I speak on behalf of everyone when I say we appreciate all your hard work and the vital role you play in the practical application of COVID-19 testing.”

        For further information please email randoxpr@randox.com

        Want to know more about Randox?

        Contact us or visit our homepage to view more.

        Our Randox Products and Services

        REAGENTS

        RX SERIES

        ACUSERA

        BIOCHIP


        Norbrook partners with Randox on staff screening programme for COVID-19

        News       About Us       COVID-19

         

        27 May 2020

        Norbrook partners with Randox on staff screening programme for COVID-19

        Pharmaceuticals company Norbrook Laboratories has revealed that it will be the first company in Northern Ireland to install an innovative COVID-19 testing platform for on-site staff screening.

        The Newry-based firm, which specialises in the development of pharmaceuticals for the veterinary industry, will begin testing for its workforce in the coming weeks, to provide reassurance and peace of mind for colleagues and for their families, without impacting on the public health need.

        The COVID-19 screening programme at Norbrook is being facilitated by diagnostic technology from global diagnostics company Randox, one of the partners within the national COVID-19 testing programme.

        David Ferguson, Managing Director at Randox Food Diagnostics explained;

        “Collectively we are all working towards a timely return to a more normal society, which will see companies reopening and people returning to work.

        “To facilitate this recovery of the economy, without compromising the health of workers or of the wider general public, workplaces have a responsibility to provide a safe working environment.

        “We know that the health of Norbrook’s staff is their priority and as such it is great to see them taking a proactive approach to testing.”

        The COVID-19 screening programme at Norbrook is the first in Northern Ireland being facilitated by an innovative testing platform capable of processing results in 2hours 30 mins.

        The technology, named the Vivalytic, can screen for SARS-CoV-2, the virus that causes COVID-19, as well as a range of other viral and bacterial infections including Influenza A and B, Pneumonia and other coronaviruses.

        David added;

        “Randox is fully committed to supporting the national effort to fight COVID-19 by testing at scale, and as we continue to work alongside the government and ramp up our testing capabilities, we welcome the fact that other organisations are also adopting our innovative COVID-19 testing technologies to address their own particular testing needs.

        “The Vivalytic, which provides high quality molecular testing for COVID-19, on-site and without the need for laboratory experience, is a unique space-saving, hygienic solution for personnel COVID-19 testing in any setting and will help a wide variety of industries get back to business by ensuring the highest level of safety.”

        Denise Collins, Norbrook Human Resources Director, concluded;

        “We’re proud to be working with a company like Randox which has such vast experience in the diagnostics industry and was subsequently able to respond so quickly to the COVID-19 pandemic.

        “That this world-leading technology is available from a Northern Ireland-headquartered company presents a unique opportunity for workplaces here to quickly and easily implement a staff screening programme, and at the same time demonstrate a high standard of duty of care that should be shown by employers to their employees.”

        For further information about the Vivalytic please email marketing@randox.com

         

        Want to know more about Randox?

        Contact us or visit our homepage to view more.

        Our Randox Products and Services

        REAGENTS

        RX SERIES

        ACUSERA

        BIOCHIP


        Randox calls upon NI engineers to build COVID-19 testing platforms

        randox-careers

        About Us       News        Contact

        05 April 2020

        COVID-19 Engineering Recruitment Drive

         

        RANDOX CALLS UPON NI ENGINEERS TO BUILD COVID-19 TESTING PLATFORMS

        Randox Laboratories has today announced it is recruiting 160 mechanical, electrical and manufacturing engineers to enhance its capacity for COVID-19 testing.

         The engineers, who are due to begin work at the Randox Science Park from the middle of May, will be involved in the fast-tracked development of specialist molecular analysers used to detect the presence of COVID-19.

        These testing platforms will be used to further enhance the government’s national testing scheme for key workers, as well as to facilitate testing more broadly across the general populace.

        Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;

        “It is Randox’s priority to ensure that we support the UK’s effort to fight COVID-19, by testing at scale. We know that this is the most effective way to both save lives and promote a timely return to a more normal society.

        “We continue to ramp up our COVID-19 testing capabilities – not only by increasing our production of testing kits, but also by accelerating the build schedule for the testing analysers on which the tests are performed.

        “We are aiming, by working at maximum efficiency in a greatly accelerated time frame of 6-7 weeks, to manufacture 200 of our most state-of-the-art testing platforms, which will greatly enhance our testing capacity at Randox.”

        Randox has, in recent weeks, established a number of new teams responsible for the development, manufacturing and distribution of COVID-19 testing kits for the national testing programme.

        The company is also interested in speaking to anyone with experience in mechanical, electrical or manufacturing engineering. Invest Northern Ireland is helping by contacting companies which may be able to temporarily release resources to help meet this urgent staffing requirement.

        Dr FitzGerald added;

        “To meet the unprecedented demand for COVID-19 testing, we have been redeploying our own personnel to various COVID-19 critical departments, but are now also recruiting for a number of specialist disciplines.

        “Everyone at Randox has a vital role to play in the practical application of COVID-19 testing, and for engineers in particular, this is a unique opportunity to make a positive impact in the fight against COVID-19, by directly contributing in no small part to the national testing programme.”

        Anyone interested in the Randox COVID-19 Engineering Drive should apply at careers.randox.com

        Want to know more?

        Contact us or visit our Randox Careers

        Find out more about Randox Careers

        Careers News

        Vacancies

        Our People

        Careers Website


        Health Secretary Matt Hancock publicly thanks Randox for ‘stepping up to the mark’

        News       About Us       COVID-19

         

        24 April 2020

        Health Secretary Matt Hancock thanks Randox staff

        Health Secretary Matt Hancock publicly thanks Randox for ‘stepping up to the mark’

        On 23 April 2020, UK Health Secretary Matt Hancock personally thanked staff at Randox for the work we have done and continue to do, during the daily coronavirus briefing from Downing Street.

        He said;

        “I want to take this moment to applaud the private companies who have been involved…Boots, Amazon, Thermo Fisher, Randox, Rosch, Oxford Nanopore, GSK and Astrazeneca. They have really stepped up to the mark and I am grateful for each and every one.”

        It is Randox’s priority to ensure that we contribute to the global effort to fight COVID-19, by testing at scale. We are therefore absolutely committed to the government testing scheme, which is focusing on key workers and the maintenance of critical national infrastructure – including that of the NHS.

        In order to meet the requirements of this scheme, we have undertaken considerable reorganisation within the company by redeploying personnel – often to newly formed departments and newly formed teams.  Everyone at Randox has a critical role to play in the practical application of COVID-19 testing and we appreciate all the hard work, patience, and flexibility of our staff.

        Our work has greatly expanded the capacity for testing in the UK and we will continue to ramp up our capabilities, to both save lives and promote a timely return to a more normal society.

        What we are doing is making a real and positive difference.

          For further information please email randoxpr@randox.com

          To watch the full version of the Daily Coronavirus Briefing from 23rd April, please click here.

           

           

          Want to know more about Randox?

          Contact us or visit our homepage to view more.

          Our Randox Products and Services

          REAGENTS

          RX SERIES

          ACUSERA

          BIOCHIP


          Official statement from Randox on Covid-19 testing

          News       About Us        Randox Biochip

           

          03 April 2020

           

          OFFICIAL STATEMENT FROM RANDOX

          On the emergence of the Covid-19 threat Randox utilised their years of regulated diagnostic experience to quickly develop and robustly validate a test for the Covid-19 virus.  Randox had significant confidence in this test and presented them to Public Health England (PHE) for evaluation.  PHE were managing this validation process for each of England, Wales, Scotland and Northern Ireland.

          The UK Government showed significant confidence in Randox’s capability and conducted full engagement and planning subject to PHE acceptance of the Randox test.  When PHE acceptance was granted, the Randox part in the national plan had been prepared and was quickly initiated.

          We understand that the national plan for the testing of key workers is exactly that, a national plan, inclusive of Northern Ireland.  Initially relatively small numbers of tests were sent to the areas of significant national threat in London.

          The planning for the national distribution of test kits is being managed by the various relevant statutory agencies however Randox has made the case that tests should be made available locally.  Following that engagement, tests have now been made directly available within Northern Ireland and Randox will continue to support Northern Ireland within the UK national plan.

          Randox have acted with speed and initiative throughout this crisis and will continue to ramp up our testing capability to support the national testing plan for key workers in Northern Ireland.

          Every part of Randox’s business is focused on doing everything we can to support the Covid-19 testing programme, to both save lives and ensure the speediest possible return to a more normal society.

          For more information please contact the Randox PR team by emailing randoxpr@randox.com

           

          QNOSTICS

          QCMD

          BIOSCIENCES


          Randox joins government drive on COVID-19 tests for frontline NHS staff

          News       About Us        Randox Biochip

           

          27 March 2020

           

          Randox Laboratories is partnering with the government to develop a new coronavirus testing programme in which NHS staff will be first in line.

          The new service, which will be free, will help to end the uncertainty of whether NHS staff need to stay at home. Those who test negative for coronavirus will be able to return to work – enhancing the capacity of the NHS and social care to treat patients and care for those in community settings, with plans for a full roll-out for health, social care and other frontline workers.

          Randox are providing high volume home sample collection kits and laboratory testing.

          Randox CEO Dr Peter FitzGerald, said:

          “We have an excellent Covid-19 assay and we are committed to supporting the government and this important initiative to test key workers and support vital public services.

          “Randox Laboratories is now operational for COVID-19 testing and will be ramping up extensively in the coming weeks. This will provide extensive employment opportunities for laboratory and support staff.

          “Our first tests have gone to the London Ambulance Service and we look forward to playing our role in ensuring that this critical capability continues to operate.”

          To offer its coronavirus testing capabilities to the new programme, Randox’s COVID-19 test recently underwent evaluation from, and has been accepted by, Public Health England.

          In its evaluation of the Randox COVID-19 test, Public Health England’s report noted that the assay correctly identified all positive and negative samples without exception.

          As a result the government are proceeding to utilise the Randox COVID-19 test in the new testing programme for NHS staff, with an exceptionally high degree of confidence.

          Two simultaneous tests are carried out on the proprietary Randox Biochip, in line with guidelines from the Centres for Disease Control and Prevention, and the World Health Organisation.

          Health Secretary Matt Hancock said:

          “We want to save lives, protect the most vulnerable, and relieve pressure on our NHS.

          “Healthcare staff are key in our fight against the virus and I want to ensure that any frontline NHS or care worker who has symptoms of coronavirus or who has a family member with symptoms can be tested quickly and reliably.

          “I pay tribute to the generosity and public spirit of Britain’s universities, research institutes and companies who have lent us their equipment without hesitation.”

          Dr Jenny Harries, Deputy Chief Medical Officer, said:

          “Laboratory-based testing on this scale is a little like building the medical equivalent of a car factory. We are assembling many different parts, some of them quite specialised and hard to find, then getting them to work accurately together in a highly co-ordinated process. There are bound to be teething problems, so we cannot switch on hundreds of thousands of lab tests overnight. But we hope that soon these hub laboratories will be operating round the clock, allowing us to significantly scale up our testing.”

          For more information or to arrange interviews, please contact the Randox PR team by emailing randoxpr@randox.com

          QNOSTICS

          QCMD

          BIOSCIENCES


          Hospitals in Wuhan and Guangzhou roll out new coronavirus test developed by Randox scientists

          News       About Us        Randox Biochip

           

          02 March 2020

           

           

          Hospitals in Wuhan and Guangzhou roll out new coronavirus test developed by Randox scientists

          Randox’s pioneering new test for coronavirus, which identifies COVID-19 and differentiates it from nine other respiratory infections, is to be used in Chinese hospitals.

          The comprehensive test, which is being shipped this week to hospitals in Wuhan and Guangzhou, has been developed on Randox’s unique technology platform, the Biochip.  This allows for each patient to be simultaneously tested for a range of respiratory infections inclusive of all known coronaviruses.

          The Coronavirus Biochip tests each single patient sample for the SARS-CoV-2 virus that causes COVID-19, as well as nine other respiratory viruses, including SARS, MERS, and Influenza A and B. This enables clinicians to quickly and efficiently differentiate between potentially lethal and non-lethal infections, prioritise patients and administer appropriate and timely treatment.

          Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;

          “Current technologies being used to diagnose COVID-19 are focused on simply detecting the presence or lack of this singular strain and therefore neglect to differentiate it from other respiratory infections. At Randox we have developed a multiplex Viral Respiratory Infection Array that tests for COVID-19 and nine other infections simultaneously, and are delighted that this new technology will be deployed in Wuhan and other cities across China.

          “The Coronavirus Biochip will eliminate the need for multiple back-and-forth tests before the root cause of symptoms is found, thereby empowering clinicians to make faster and better-informed decisions.”

          Due to be used in hospitals in Wuhan, the epicentre of the coronavirus outbreak, as well as in The First Affiliated Hospital of Guangzhou Medical University, the new testing technology is capable of processing 324 patient samples, generating 3240 reportable results, in just 8 hours.

          The panel includes two tests for COVID-19, a specific test (SARS-CoV-2) and a confirmatory test (Sarbecoviris) on the same panel, as recommended by the World Health Organisation. This avoids the need to repeat the test, and importantly, reduces the likelihood of incorrect diagnosis, ensuring appropriate containment and reducing the risk of further contamination. This faster and more comprehensive testing will ultimately support the health service in China by facilitating the efficient use of valuable healthcare resources.

          Byron Wang, CEO of Beijing Promed, Randox’s partner in providing the new coronavirus test in China, commented;

          “We welcome the support of the global community in assisting us combat COVID-19 at this time. Randox is a highly regarded In Vitro Diagnostic company in China and has supported our market with high quality products for many years. We look forward to supplying this test to hospitals located within the area of greatest need and believe it will make a real difference.”

          Dr FitzGerald concluded;

          “Randox is committed to saving and improving lives on a global scale and we know that this new COVID-19 test will make a significant contribution to the global coronavirus containment effort.”

          The Coronavirus Biochip tests simultaneously for Coronavirus SARS-CoV-2 (COVID-19), Sarbecoviris (SARS, SARS like, COVID-19), Coronavirus 229E/NL63, Coronavirus OC43/HKUI, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Adenovirus A/B/C/D/E, Enterovirus A/B/C, Influenza A, Influenza B and Rhinovirus A/B.

          The Randox Coronavirus Biochip complies with guidelines from the Centres for Disease Control and Prevention and the World Health Organisation.

          For more information or to arrange interviews, please contact the Randox PR team on 028 9442 2413 or email randoxpr@randox.com

           

          QNOSTICS

          QCMD

          BIOSCIENCES


          Downpatrick announce Randox as new sponsor of Ulster National

          News       About Us       Randox Health

           

          29 January 2020

          Randox Ulster National, Sunday March 22, Downpatrick Racecourse

          Randox has today been announced as the sponsor of the Ulster National at Downpatrick Racecourse for the next five years.

          Downpatrick Racecourse, winner of the ‘Sports Venue of the Year’ in both 2018 and 2019 at the Northern Ireland Hospitality Awards, hosts the €50,000 Randox Ulster National, on Sunday March 22, their flagship race day.

          Randox, a global innovative healthcare diagnostics company, based in Crumlin, County Antrim, was founded in 1982 by medical scientist and keen horseman Dr Peter FitzGerald. The five-year sponsorship of the Ulster National sees Randox expand a racing sponsorship portfolio which includes the Randox Health Grand National at Aintree, and title sponsorship of the entire three-day Randox Health Grand National Festival at the Liverpool racecourse.

          The Randox Ulster National is one of the most historic races on the racing calendar. Run over three miles and four furlongs, the race was first run in 1939 and has a long and illustrious history.

          Caughoo won the 1945 and 1946 Ulster National before winning the 1947 Aintree Grand National for jockey Eddie Dempsey and Dublin-based trainer, Herbert McDowell. Laffy, owned by HRH Queen Elizabeth, The Queen Mother, won the Ulster National in 1962 and Pineau De Re also won Downpatrick’s centre piece jumps race in 2013 and subsequently went on to win the Aintree Grand National the next season (2014).

          Dr Peter FitzGerald, Randox Managing Director, commented;

          “This is an incredibly exciting time to be partnering with Downpatrick Racecourse to add the Randox Ulster National to our racing portfolio. Racing is a sport everyone can enjoy, from all different walks of life, and a partnership with Downpatrick offers us a fantastic opportunity to share our message of preventative health with a wide and engaged audience. We look forward to the first year of the Randox Ulster National, to show our commitment to this wonderful sport and to encourage people to take control of their health and wellbeing with a Randox Health Check.”

          Peter Stewart, Downpatrick Racecourse Chairman, said:

          “We are really excited to partner with such a respected global brand as Randox for our most prestigious race meeting and look forward to working closely together to create a wonderful race day for our customers and achieve our shared objectives.

           “The Randox partnership will ensure we continue to attract high calibre horses for the Randox Ulster National and further endorse its important position on the racing calendar.”

          For further information please contact Amy Millar in the Randox PR team by emailing: amy.millar@randox.com or phoning 028 9442 2413

          Want to know more about Randox?

          Contact us or visit our homepage to view more.

          Our Randox Products and Services

          REAGENTS

          RX SERIES

          ACUSERA

          BIOCHIP


          Request a meeting
          ×
          Make an Enquiry - RX series
          ×
          Make an Enquiry - Reagents
          ×
          Kit Insert Request - Reagents
          • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
          ×
          Kit Insert Request - Reagents
          • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
          ×
          Make an Enquiry - Reagents
          ×
          Make an Enquiry - Quality Control
          ×
          Make an Enquiry - RIQAS
          ×
          Make an Enquiry - RIQAS
          ×
          Make an Enquiry - Quality Control
          ×
          Make an Enquiry
          • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
          ×
          Make an Enquiry - Biochip
          • This field is for validation purposes and should be left unchanged.
          ×
          Make an Enquiry - Molecular
          • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
          • This field is for validation purposes and should be left unchanged.
          ×
          Make an Enquiry - Future Diagnostics
          ×
          Make an Enquiry - RX series (Product)
          ×
          Make an Enquiry - Quality Control
          • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
          ×
          Make an Enquiry - RIQAS
          • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
          ×
          Make an Enquiry - Reagents
          • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
          ×
          Por favor, introduzca sus datos para ver nuestro último seminario
          ×
          Wyślij zapytanie
          • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
          ×
          Wyślij zapytanie
          • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
          ×
          Wyślij zapytanie
          • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
          ×
          Wyślij zapytanie
            Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
          ×
          귀하의 문의 사항 제출
            Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
          ×
          귀하의 문의 사항 제출
          ×
          귀하의 문의 사항 제출
          ×
          귀하의 문의 사항 제출
          ×
          Downloads
          ×
          Contact

          <p>

            Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
          </p>

          ×
          Enquire Now - Coronavirus Testing
          • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details safe and secure. Read more in our Privacy Policy.
          ×